Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Todd Neale

April 02, 2026

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

News Conference News ACC 2026

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

L.A. McKeown

March 29, 2026

Presentation ACC 2026

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

Presenter: Ajay J. Kirtane

March 29, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Caitlin E. Cox

March 04, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

L.A. McKeown

March 04, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

Advertisement

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

What’s Going to Be Hot at ACC 2026

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

What’s Going to Be Hot at ACC 2025?

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

What’s Going to Be Hot at ACC/WCC 2023?

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content